This website is intended for U.S. Healthcare Professionals.
REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
REVLIMID may help patients continue the fight against relapsed or refractory MCL1*
*Patients must have received prior bortezomib.
ORR (CR + CRu + PR).
IN A PRETREATED POPULATION WHERE MOST PATIENTS HAD RECEIVED ≥3 PRIOR SYSTEMIC THERAPIES, REVLIMID PROVIDED A 26% ORR (CR + CRu + PR)
Median DOR.
A >16-MONTH MEDIAN DURATION OF RESPONSE WAS ACHIEVED IN PATIENTS WITH RELAPSED OR REFRACTORY MCL TAKING REVLIMID
DOR was defined as time from the initial response (at least PR) to documented disease progression.
Median TTR.
REVLIMID delivered responses in 2.2 months (median).
MEDIAN TIME TO RESPONSE (TTR)
ADVERSE REACTIONS1
Mantle Cell Lymphoma
- Grade 3 and 4 adverse events reported in ≥5% of patients treated with REVLIMID in the MCL trial (N=134) included neutropenia (43%), thrombocytopenia (28%), anemia (11%), pneumonia (9%), leukopenia (7%), fatigue (7%), diarrhea (6%), dyspnea (6%), and febrile neutropenia (6%)
- Adverse events reported in ≥15% of patients treated with REVLIMID in the MCL trial included neutropenia (49%), thrombocytopenia (36%), fatigue (34%), anemia (31%), diarrhea (31%), nausea (30%), cough (28%), pyrexia (23%), rash (22%), dyspnea (18%), pruritus (17%), peripheral edema (16%), constipation (16%), and leukopenia (15%)
CI, confidence interval; CR, complete response; CRu, complete response unconfirmed; DOR, duration of response; ORR, overall response rate; PR, partial response; TTR, time to response.
